Kernal Biologics
YC S20Boston, US · Founded 2016 · Delaware corporation · 20 employees · 11 known investors
Find your way into Kernal Biologics
1,044 people in our graph share verified history with the Kernal Biologics team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Jeff Ozdemir · together at Brigham and Women's Hospital (overlapped)
×3knows the team · via Massachusetts Institute of Technology
knows the team · via UT Southwestern
×2knows the team · via Harvard Medical School
knows the team · via Massachusetts Institute of Technology (MIT)
knows the team · via Intellia Therapeutics
Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.
AI & Machine LearningBiotechHealthtechMedical DevicesArtificial IntelligenceGenomicsUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (S20)
Kernal Biologics was founded in 2016 by Yusuf Erkul, Jeff Ozdemir, Burak Yilmaz, and Burak YILMAZ.
YE
Yusuf Erkulin𝕏Co-founder, CEOHe previously worked at Merck on oncology drug discovery and development, holds an M.D. from Hacettepe University, a B.S. in Biology from MIT, and an executive MBA from MIT Sloan.
JO
Jeff OzdemirinCo-founder · Head of PlatformJeff Ozdemir holds a PhD in Molecular Genetics from UT Southwestern Medical Center and completed postdoctoral training at Harvard Medical School. He previously taught biochemistry at MIT before co-founding Kernal Biologics.
BY
Burak YilmazinFounder & PresidentBurak Yilmaz holds an MS and is co-founder and lead designer at Kernal Biologics, where he works on mRNA platform technology. Previously, he founded Sentegen/Sentebiolab, a synthetic biology company focused on synthetic DNA production for research and diagnostics.
BY
Burak YILMAZinFounder & PresidentBurak Yilmaz holds an MS and previously founded Sentegen/Sentebiolab, a synthetic biology company focused on synthetic DNA production for research and diagnostics. He is co-founder and lead designer of Kernal Biologics, which develops mRNA-based therapeutics for cancer and other serious diseases.
CM
Catherine MoroskiinCo-founder2016–2018Catherine Moroski has over 20 years of preclinical research experience, including work at Intellia Therapeutics where she designed in vivo studies, developed biomarker assays, and advanced gene insertion programs for genetic disease therapeutics; her expertise includes CRISPR/Cas9 gene editing, animal model development, and regulatory support.
OY
Oguzhan YilmasNamed on SEC filing
Investors · 11
Asymmetry VenturesRichmond · $125K – $500Kvia Rob Ness · inferred
Civilization Ventures Management, LlcTiburon · $1M – $10M
FoundersX VenturesSilicon Valley
HOF CapitalNew York · $25K – $15M
Hummingbird VenturesSingapore · $500K – $10M
SAV (Scale Asia Ventures)Palo Alto
Y CombinatorSan Francisco · $500K
Amgen VenturesreportedThousand Oaks · $1M – $3M
Also in the syndicate · 3
AmgenHBM GenomicsHummingbird
Reported raises · per SEC filings
Form D private placements$20.9M disclosed across 3 of 4 rounds · 2016–2025
▶$20.1MraisedFeb 2022 · 53 investors · BiotechnologyRule 506(b)
▶$20.1MraisedFeb 2022 · 53 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yusuf ErkulExecutive Officer, Director
- Burak YilmazExecutive Officer, Director
- Offering amount
- $25.5M
- Amount sold
- $20.1M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedAug 2018 · 1 investors · Other Health CareRule 506(b)
▶$500KraisedAug 2018 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Burak YilmazExecutive Officer
- Yusuf ErkulExecutive Officer, Director
- Oguzhan YilmazDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$350KraisedSep 2016 · 2 investors · Other Health CareRule 506(b)
▶$350KraisedSep 2016 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Yusuf ErkulExecutive Officer, Director
- Catherine MoroskiExecutive Officer, Director
- Oguzhan YilmasDirector
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Kernal Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Kernal Biologics do?
- Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.
- Who founded Kernal Biologics?
- Kernal Biologics was founded by Yusuf Erkul, Jeff Ozdemir, Burak Yilmaz, Burak YILMAZ in 2016.
- Who are Kernal Biologics's investors?
- Kernal Biologics's investors include Asymmetry Ventures, Civilization Ventures Management, Llc, FoundersX Ventures, HOF Capital, Hummingbird Ventures, SAV (Scale Asia Ventures), Y Combinator, Amgen Ventures.
- How much funding has Kernal Biologics raised?
- Kernal Biologics has disclosed $20.9M raised across 3 of its 4 known rounds.
- Where is Kernal Biologics headquartered?
- Kernal Biologics is headquartered in Boston, US.